These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16601877)

  • 21. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
    Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
    Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
    Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
    Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
    Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
    Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
    Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
    Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.
    Nguyen Dinh Cat A; Escoubet B; Agrapart V; Griol-Charhbili V; Schoeb T; Feng W; Jaimes E; Warnock DG; Jaisser F
    PLoS One; 2012; 7(5):e33743. PubMed ID: 22574107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
    Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
    J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
    Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
    Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.
    Elliott PM; Kindler H; Shah JS; Sachdev B; Rimoldi OE; Thaman R; Tome MT; McKenna WJ; Lee P; Camici PG
    Heart; 2006 Mar; 92(3):357-60. PubMed ID: 16085718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiokeratomas and treatment with enzyme replacement therapy in a patient with Fabry disease.
    Merzel Šabović EK; Žerjav Tanšek M; Grošelj U; Dragoš V
    Acta Dermatovenerol Alp Pannonica Adriat; 2020 Jun; 29(2):89-91. PubMed ID: 32566958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
    Beck M
    Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.